Synchronous breast cancer and lymphoma: a case series and a review of the literature

Katharine E Cuff,1 Andrew J Dettrick,2 Boris Chern3

ABSTRACT

Four patients with synchronous breast cancer and lymphoma are described. In all cases, the lymphoma was an unexpected finding in the histopathology of the axillary lymph-node dissection. The diagnosis of synchronous malignancies poses challenges for both the diagnosing pathologist and the treating clinician.

The four patients described had an unexpected synchronous malignancy diagnosed during the workup for their breast cancer. It is a well-documented fact that patients with one treated malignancy are at an increased risk of developing a second tumour. However, the synchronous presentation of two malignancies is rare. In an autopsy study of 1870 known cancer deaths, 68 cases (3.6%) had multiple primaries, and only 15 (0.8%) of these were synchronous.1

We describe four patients who all presented within a 10-month time period to a regional hospital in Queensland Australia (table 1). This hospital treats on average 200 new breast cancer cases each year. To the best of our knowledge, this is the largest such case series in the English language literature, and it is remarkable considering the short time period over which the patients presented. Cox et al2 published a case series describing three patients who presented over a period of 15 years with breast carcinomas and coincidental axillary lymphoma, and there have been a number of similar single case reports.3–5

Factors that have been suggested as contributing to the development of synchronous malignancies include advanced age of the patient, primary or cancer-related immunological impairment and genetic predisposition to cancer.6 As our population ages, this is likely to become a more frequent occurrence. The UK population is predicted to reach 65 million by 2016. In 2006, there were 4.7 million people in the UK aged 75 and over. The number is projected to increase to 5.5 million by 2016 and to 8.2 million by 2031, a rise of 76% over 25 years.

Two of the four patients described had both the breast cancer and the lymphoma occurring in the same lymph node. This has been rarely described in the literature. Possible explanations have been put forward to explain why this is an unusual finding, including the fact that the lymphoma may obliterate the lymphatic channels if it occurs first,6 or may lead to a local reduction in cytokine induced adhesion of breast cancer cells to the axillary lymph nodes.7 This situation could potentially impact on both staging and prognosis of the patient. Benoît et al describe a patient with breast cancer and negative sentinel lymph nodes.8 Complete level I/II axillary lymph node dissection diagnosed low-grade lymphoma. Metastatic breast carcinoma was found in one non-sentinel node which was free from lymphoma. Sentinel lymph-node biopsy alone would have led to incorrect staging and therefore potentially inadequate treatment of the breast cancer. As our two patients with lymph-node involvement had a clinically palpable lymphadenopathy, they progressed directly to axillary dissection, and their sentinel nodes were not identified. Therefore, we are unable to comment on whether they would have had negative sentinel nodes.

Patients with lymphoma tend to be chronically immunosuppressed. As well as predisposing them to the initial development of a second malignancy, it may also impact on its behaviour. Squamous-cell carcinoma has been noted to have an increased risk of metastasis and mortality in patients with chronic lymphocytic leukaemia.9 This more aggressive behaviour has been attributed to the patient’s immunosuppressed state, and it is possible that breast cancer may behave similarly.

An important point highlighted by these cases is that, in the situation of obvious axillary lymphadenopathy and an impalpable breast primary, this does not always indicate metastatic disease. The clinician needs to maintain a high index of suspicion about the possibility of synchronous malignancies, and a biopsy from both breast and axilla may be required prior to planning surgery (table 1).

Synchronous malignancies pose both a diagnostic challenge to the pathologist and a management challenge to the clinician. If a patient has a negative sentinel node biopsy for carcinoma but is diagnosed as having an unexpected lymphoma, the possibility of a completion axillary dissection should be discussed, as this may impact on staging of the breast carcinoma. Also, a decision will need to be made regarding which malignancy should be discussed, as this may impact on staging of the breast carcinoma. Also, a decision will need to be made regarding which malignancy should
Table 1  Case descriptions

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
<th>Case 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Case description</strong></td>
<td>74-year-old: self-detected right-sided breast lumps</td>
<td>74-year-old: mammographically detected left breast lesion</td>
<td>79-year-old: mammographically detected right breast mass and axillary lymphadenopathy</td>
</tr>
<tr>
<td><strong>Examination findings</strong></td>
<td>Multiple hard mobile right axillary lymph nodes</td>
<td>NAD</td>
<td>Obvious large mobile mass within the right axilla; no other regional lymphadenopathy detected; no palpable masses within the breast</td>
</tr>
<tr>
<td><strong>Surgery</strong></td>
<td>Modified radical right mastectomy with level 2 axillary lymph node dissection</td>
<td>Wide local excision and sentinel node biopsy</td>
<td>Modified radical right mastectomy with axillary mass excised in continuity with the whole breast</td>
</tr>
<tr>
<td><strong>Breast-cancer histopathology</strong></td>
<td>Multicentric invasive ductal breast carcinoma with two identified tumours. Tumour 1 was 30 mm, grade 2 (figure 1) and tumour 2 was 25 mm, grade 3; both tumours were oestrogen receptor and Her-2 CISH positive</td>
<td>17 mm, grade two, invasive lobular breast carcinoma oestrogen and progesterone receptor positive; Her-2 negative</td>
<td>No evidence of carcinoma within the breast tissue and it was presumed that the entire lesion had been removed during the core biopsy</td>
</tr>
<tr>
<td><strong>Axillary lymph-node histopathology</strong></td>
<td>Metastatic ductal carcinoma was identified in 2 of the 10 nodes with extranodal spread in one; the remainder of the lymph nodes were involved by small lymphocytic lymphoma (figure 2); immunohistochemical profile of the infiltrate was positive for CD5, CD19 and CD20; lambda light chain and CD23 were weakly positive consistent with chronic lymphocytic leukaemia which represents the same disease process</td>
<td>No evidence of metastatic breast carcinoma in sentinel node however there were features suggesting low-grade B cell lymphoma; further immunoperoxidase stains were positive for B cell antigens CD 10 and CD 20 as well as strongly positive for bcl 2 protein, consistent with a diagnosis of grade 1 follicular B cell lymphoma</td>
<td>Twenty-one lymph nodes identified; the majority were partially replaced with a mixed infiltrate including eosinophils, plasma cells and large atypical cells with the occasional Reed Sternberg cell; the large cells stained positive for CD 15 and CD 30 and negative for leucocyte common antigen CD 45; the final WHO classification was classical Hodgkin lymphoma</td>
</tr>
<tr>
<td><strong>Management</strong></td>
<td>Multimodal treatment for the high risk breast cancer was recommended including chemotherapy, radiation, trastuzumab and hormonal therapy; haematology workup diagnosed CLL Rai Stage 0; the patient is being observed</td>
<td>Absolute benefit of chemotherapy was estimated at less than 2% and therefore was not recommended; the patient underwent 6 weeks of adjuvant radiotherapy followed by an aromatase inhibitor; haematology workup involved staging with PET and BMAT and the decision to adopt a watchful wait approach was made, given the low-grade nature of the lymphoma</td>
<td>The patient’s stage 1 breast cancer was treated with hormonal therapy alone; after haematological workup, her Hodgkin lymphoma was classified as a stage 1A and local irradiation was chosen as initial treatment</td>
</tr>
</tbody>
</table>

BMAT, bone marrow aspirate and trephine; CISH, chromogenic in situ hybridization; Her-2, Human epidermal growth factor receptor 2; NAD, no abnormalities detected.

Figure 1  Mastectomy specimen showing grade 2 invasive ductal carcinoma (H&E, original magnification ×200).

Figure 2  Axillary lymph node specimen showing effacement of the normal architecture by a monotonous population of small malignant lymphocytes. A ‘proliferation centre’ (pale zone) which is characteristic of small lymphocytic lymphoma can be seen to the left. A microscopic metastatic deposit of breast carcinoma can be seen to the right, under the capsule (H&E, original magnification ×40).
Take-home messages

- Synchronous malignancies are rare, but an ageing population may make them a more frequent occurrence.
- Patients with low-grade lymphomas are susceptible to developing a second malignancy, and thus their pathological specimens require careful examination.
- In the situation of an impalpable breast cancer with palpable axillary lymphadenopathy, it cannot be assumed that the patient has metastatic breast cancer; biopsy of both the breast lesion and axillary nodes may be indicated.

Competing interests None.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.

take priority with treatment, and thorough staging investigations will need to be performed for both primaries.

REFERENCES